Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Biliary Tract Neoplasms × Temozolomide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioblastoma 136 Glioma 56 Brain Neoplasms 55 Gliosarcoma 42 Central Nervous System Neoplasms 42 Astrocytoma 34 Oligodendroglioma 27 Melanoma 25 Neuroblastoma 14 Sarcoma, Ewing 9 Sarcoma 9 Neuroendocrine Tumors 9 Neoplasm Metastasis 9 Medulloblastoma 9 Lung Neoplasms 8 Carcinoma, Non-Small-Cell Lung 8 Recurrence 7 Neoplasms 7 Ependymoma 7 Diffuse Intrinsic Pontine Glioma 7 Breast Neoplasms 7 Rhabdomyosarcoma 6 Ovarian Neoplasms 6 Lymphoma 6 Colorectal Neoplasms 5 Carcinoma, Neuroendocrine 5 Small Cell Lung Carcinoma 4 Pheochromocytoma 4 Adenoma, Islet Cell 4 Uveal Melanoma 3

Interventions

Gemcitabine 35 Cisplatin 27 Oxaliplatin 19 Capecitabine 16 Fluorouracil 13 Leucovorin 12 Irinotecan 10 pembrolizumab 9 lenvatinib 8 durvalumab 7 Bevacizumab 7 S 1 (combination) 6 apatinib 5 Nivolumab 5 tremelimumab 4 Trastuzumab 4 Injections 4 Docetaxel 4 trametinib 3 titanium silicide 3 irinotecan sucrosofate 3 envafolimab 3 camrelizumab 3 atezolizumab 3 Drug Therapy 3 toripalimab 2 surufatinib 2 pertuzumab 2 gemcitabine-oxaliplatin regimen 2 brigimadlin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04796454 2022-06-01

PAMICC

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡